Opinion|Videos|July 16, 2024
Perspectives on Shared Decision-Making in the Treatment of CLL
Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Examine the importance of patient preferences and patient involvement in the shared decision-making process to individualize treatment and improve outcomes.
- How do you assess and incorporate patient preferences into treatment selection?
- What insights/implications do data recently presented at EHA 2023 offer?
Advertisement
Related to this article
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
2
FDA Flashback: Breast Cancer Decisions and News From July 2026
3
Dr Wong on the FDA Approval of Vusolimogene Oderparepvec-wtpg Plus Nivolumab in Melanoma
4
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
5